SVRA FDA calendar & decision history Savara · 1 upcoming · 1 past FDA decision
Upcoming FDA catalysts SVRA · Nov 22, 2026 MOLBREEVI (molgramostim inhalation) - (IMPALA-2) — Autoimmune pulmonary alveolar proteinosis (aPAP) BLA FDA decision history (1) May 27, 2025✕ CRL source-verified See the full 2026 PDUFA calendar → This page aggregates SVRA's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio